Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540419 | 1.00 | NR3C1 (0.50) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5540438 | 1.00 | NR3C1 (0.50) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5540427 | 1.00 | NR3C1 (0.50) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5540442 | 1.00 | NR3C1 (0.50) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL14496148 | 0.88 | MCHR1 (0.40) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5540222 | 0.88 | MCHR1 (0.40) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5540217 | 0.88 | MCHR1 (0.40) | NR3C1PGRARDRD4MCHR1 | |
| SCHEMBL5534973 | 0.85 | CHRNA7 (0.46) | NR3C1PGRARTAS1R3TAS1R1 | |
| SCHEMBL5537977 | 0.85 | CHRNA7 (0.46) | NR3C1PGRARTAS1R3TAS1R1 | |
| SCHEMBL5534982 | 0.85 | CHRNA7 (0.46) | NR3C1PGRARTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129359-A1 | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129359-A1 | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129359-A1 | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129359-A1 | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, IL1B, PTGS1 | NR3C1 190/4885PGR 2358/4885AR 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.